Celgene Corp. has taken its cheque book out to sign a second neurodegenerative disease pact this month, paying $100m upfront and a $50m equity investment to team up with Prothena Corp. PLC and develop therapies to tackle conditions such as Alzheimer's and amyotrophic lateral sclerosis.
The multi-targeted collaboration will focus on three proteins implicated in neurodegenerative diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?